Melanoma neoantigen vaccines: Are we getting more personal now?


KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.

More about this publication

Med (New York, N.Y.)
  • Volume 5
  • Issue nr. 4
  • Pages 288-290
  • Publication date 12-04-2024

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.